Importantly, patients positive for both JCV and intrathecal IgM had similar risk of developing PML as patients seronegative for JCV, suggesting these antibodies substantially contribute to JCV defences in the CNS [11]. This evidence concerns the gene CD40LG and progressive multifocal leukoencephalopathy.